undamentalytics Newsletter

Agilon Health, Inc. valuation and forecast

Explore the models for Agilon Health, Inc., adjust their assumptions and compare your own valuation with the platform's.

Your valuation workspace

What is AGL worth to you?

Start with the company's financial data. Make the assumptions your own.

5 models available

01 / Assumptions

Follow the forecast

The cash flows behind your value

USD per share
View annual figures
Forecast yearCash flow / share

Negative cash flows are shown in terracotta. Before the terminal value and equity bridge. Residual-income models show excess earnings; dividend models show dividends.

See the range of possibilities

Compare and combine your models

Your weighted value—

Weights start with the platform's included models. Change them to build your own combination. Select a model name to edit its assumptions.

ModelYour value / shareWeight

The platform's price and consistency filters are not reapplied to your scenarios.

Other model types 17 unavailable for AGL

Justified price-to-book

return on equity is not positive

Revenue-to-maturity model

revenue and margins don't support a positive value

Cash-flow DCF

This model does not apply to this company with the available financial data.

P/B vs return on equity

This model does not apply to this company with the available financial data.

Peer price-to-book

This model does not apply to this company with the available financial data.

Peer P/E

This model does not apply to this company with the available financial data.

Peer price-to-FFO

This model does not apply to this company with the available financial data.

Peer price-to-sales

This model does not apply to this company with the available financial data.

P/E comparison

This model does not apply to this company with the available financial data.

PEG comparison

This model does not apply to this company with the available financial data.

Two-stage dividend discount

This model does not apply to this company with the available financial data.

Growing-dividend model

This model does not apply to this company with the available financial data.

REIT funds from operations

This model does not apply to this company with the available financial data.

Utility earnings

This model does not apply to this company with the available financial data.

Book value / net assets

This model does not apply to this company with the available financial data.

Reported crypto treasury NAV

This model does not apply to this company with the available financial data.

Proved-reserve NAV

This model does not apply to this company with the available financial data.

Model values are estimates under the assumptions shown. They are not share-price forecasts or investment advice.

Valuation models compared

Growth cash-flow modelRevenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged.
~$170~$110–$210
Forward price-to-earnings vs peersleft out of the combined value: far from the other models (more than 3x away from their median)
~$41~$34–$60
Forward price-to-sales vs peersNext year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.
~$310~$290–$830
Models combinedweighted average of 2 models; primary model counts double
~$200~$170–$310

Different models answer different questions: the cash-flow models ask what the business generates for owners; the peer multiples ask what similar companies in our coverage trade on. Where they disagree, the gap is the story. Projections are estimates based on current data, updated daily. Not investment advice. How each model works.

Analyst recommendations

15 analysts, Nov 2026
Buy533%
Hold960%
Sell17%

Monthly trend

  1. Nov 20265915
  2. Oct 20265915
  3. Sep 202641116

Counts of recommendations published by analysts covering Agilon Health, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

AGL valuation questions

How does Fundamentalytics value Agilon Health, Inc.?
We use the models that fit Agilon Health, Inc.'s business and available financial data: growth cash-flow model, forward price-to-sales vs peers. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved October 26, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Agilon Health, Inc.

Compare with peers